Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation

Jing Zhou, Guo-Dong Lu, Chye-Sun Ong, Choon-Nam Ong and Han-Ming Shen
Jing Zhou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guo-Dong Lu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chye-Sun Ong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Choon-Nam Ong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han-Ming Shen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0071 Published July 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Andro sensitizes human cancer cells to TRAIL-induced apoptosis. A, TRAIL-induced apoptosis in human cancer cells. HepG2, HCT116, and HeLa cells were treated with indicated concentrations of TRAIL for 24 h. B, Andro-induced apoptosis in human cancer cells. Cancer cells were treated with indicated doses of Andro for 24 h. C, sensitization effect of Andro on TRAIL-induced apoptosis. HepG2, HCT116, and HeLa were pretreated with the indicated concentration of Andro for 2 h followed by treatment with a subtoxic concentration of TRAIL (10 ng/mL for HepG2 and 1 ng/mL for HCT116 and HeLa) for another 12 h. The percentage of apoptosis was determined using DAPI staining. Mean ± SD of three independent experiments. Representative images of HepG2 cells with various treatments were photographed using a normal light microscope and an inverted fluorescence microscope. Magnification, ×200.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Andro enhances the caspase cascade triggered by TRAIL. A, Andro promotes TRAIL-induced caspase activation. HepG2 cells were pretreated with 15 μmol/L Andro for 2 h followed by treatment with TRAIL (10 ng/mL) for indicated periods. Cell lysates were collected and subjected to Western blot for detecting the cleavage of caspase-8, caspase-3, and PARP. B, caspase inhibitors block PARP cleavage induced by Andro and TRAIL. C, caspase inhibitors block apoptosis induced by Andro and TRAIL. B and C, HepG2 cells were pretreated with Z-IETD-CHO (25 μmol/L), Z-DEVD-CHO (25 μmol/L), or Z-VAD-FMK (25 μmol/L) for 30 min followed by combined treatment of Andro (15 μmol/L) for 2 h and then TRAIL (10 ng/mL) for another 12 h. Cells were collected for measurement of PARP cleavage by Western blot (B) or determination of cell death using DAPI staining (C). Mean ± SD of three independent experiments. Magnification, ×200.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Andro up-regulates DR4 transcription. A, time-dependent up-regulation of DR4 protein level by Andro. HepG2 cells were treated with Andro (15 μmol/L) for 2 h followed by TRAIL (10 ng/mL) for indicated periods. Cell lysates were collected for Western blot to detect protein expression level of various TRAIL death receptors. B, effects of Andro on the cell surface expression of DR4 and DR5. HepG2 cells were incubated with Andro (15 μmol/L) for 6 h and the cell surface expression of DR4 and DR5 proteins was analyzed by flow cytometry. X axis, fluorescence intensity; Y axis, relative number of cells. Representative of three independent experiments. C, effects of Andro and TRAIL on DR4 and DR5 mRNA level. HepG2 cells were treated with Andro (15 μmol/L) for 2 h followed by TRAIL (10 ng/mL) for indicated periods. The mRNA levels of DR4 and DR5 were measured by reverse transcription-PCR. Glyceraldehyde-3-phosphate dehydrogenase was used as an internal control. D, DR4 blocking antibody suppresses the cleavage of caspase-8 and PARP induced by Andro and TRAIL. HepG2 cells were pretreated with DR4 or DR5 blocking antibodies (10 μg/mL) for 30 min followed by pretreatment with Andro (15 μmol/L × 2 h) and then TRAIL (10 ng/mL) for another 12 h. At the end of treatment, cell lysates were collected for Western blot. E, DR4 blocking antibody prevents Andro-sensitized apoptosis. HepG2 cells were treated as indicated in D. At the end of treatment, cell death was determined using DAPI staining. Magnification, ×200.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    p53 is required for DR4 up-regulation and enhanced apoptosis by Andro. A, Andro promotes p53 protein accumulation. HepG2 cells were treated with Andro (15 μmol/L) for 2 h followed by TRAIL (10 ng/mL) for indicated periods. p53 and DR4 protein levels were detected by Western blot. B, p53 knockdown prevents Andro-induced DR4 up-regulation. HepG2 cells were transfected with scrambled siRNA or p53 siRNA for 24 h. Cells were treated with Andro (15 μmol/L) for 6 h. At the end of treatment, cells were collected for detection of p53 and DR4 by Western blot. C, p53 knockdown suppresses apoptosis induced by Andro and TRAIL. After p53 knockdown, HepG2 cells were treated with Andro (15 μmol/L) for 2 h followed by TRAIL (10 ng/mL) for 12 h. Cells were assessed using DAPI staining. Representative of three independent experiments. Magnification, ×200.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Andro sensitizes TRAIL-induced apoptosis in p53 wild-type cancer cells but not in p53-deficient cancer cells. A, HepG2 and Hep3B cells were pretreated with Andro (15 μmol/L) for 2 h followed by TRAIL (10 ng/mL) for another12 h. The percentage of apoptosis was determined using DAPI staining. Mean ± SD of three independent experiments. Magnification, ×200. B, HCT116 p53 wild-type cells and HCT116 p53 knockout cells were pretreated with Andro (15 μmol/L) for 2 h followed by TRAIL (1 ng/mL) for another12 h. The percentage of apoptosis was determined using DAPI staining. Mean ± SD of three independent experiments. Magnification, ×200. C, Andro fails to enhance DR4 level in HCT116 p53 knockout cells. HCT116 p53 wild-type cells and HCT116 p53 knockout cells were treated with Andro (15 μmol/L) for 6 h or 12 h. At the end of treatment, cells were collected for detection of p53, DR4, and p21 using Western blot.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Andro promotes JNK activation, p53 stabilization, and DR4 up-regulation in ROS-dependent manner. A, Andro induces JNK activation. HepG2 cells were treated with Andro (15 μmol/L) for 2 h followed by TRAIL (10 ng/mL) for indicated periods. At the end of treatment, cell lysates were collected for the detection of protein level of phospho-JNK, total JNK, phospho-p53 Thr81, p53, DR4, and α-tubulin using Western blot. B, NAC and SP600125 abrogate Andro-induced JNK activation, p53 phosphorylation, and stabilization. HepG2 cells were pretreated with NAC (2.5 mmol/L for 30 min) or SP600125 (20 μmol/L for 30 min) followed by the treatment of Andro (15 μmol/L × 2 h) and then TRAIL (10 ng/mL) for another 6 h. C, NAC and SP600125 prevent Andro-induced DR4 up-regulation. Cells were first pretreated with NAC and SP600125 as described in B followed by Andro (15 μmol/L × 2 h) and then TRAIL (10 ng/mL) for another 3 h (for detection of DR4 mRNA level) and 6 h (for detection of DR4 protein level). D, NAC prevents Andro-induced cell surface expression of DR4. HepG2 cells were pretreated with NAC as described above followed by Andro (15 μmol/L) for 6 h. The cell surface expression of DR4 was measured using flow cytometry as described in B. Representative of three independent experiments. E, NAC and SP600125 inhibit apoptosis induced by Andro and TRAIL. HepG2 cells were treated with Andro (15 μmol/L × 2 h) followed by TRAIL (10 ng/mL) for another 12 h. The percentage of apoptosis was measured with DAPI staining. Mean ± SD of three independent experiments. Magnification, ×200.

Additional Files

  • Figures
  • Supplementary Material, Zhou et al

    Files in this Data Supplement:

    • Supplementary Fig. S1
PreviousNext
Back to top
Molecular Cancer Therapeutics: 7 (7)
July 2008
Volume 7, Issue 7
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
Jing Zhou, Guo-Dong Lu, Chye-Sun Ong, Choon-Nam Ong and Han-Ming Shen
Mol Cancer Ther July 1 2008 (7) (7) 2170-2180; DOI: 10.1158/1535-7163.MCT-08-0071

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation
Jing Zhou, Guo-Dong Lu, Chye-Sun Ong, Choon-Nam Ong and Han-Ming Shen
Mol Cancer Ther July 1 2008 (7) (7) 2170-2180; DOI: 10.1158/1535-7163.MCT-08-0071
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
  • MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
  • Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement